Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients

Abstract Introduction The EXPEDITION-8 clinical trial has demonstrated that treatment-naïve patients with compensated cirrhosis (TN/CC) of HCV genotypes 1–6 can achieve a 98% intent-to-treat sustained virologic response rate 12 weeks post-treatment with an 8-week glecaprevir/pibrentasvir (G/P) regim...

Full description

Bibliographic Details
Main Authors: Nancy Reau, Wei-Han Cheng, Qiujun Shao, Steven E. Marx, Hannah Brooks, Anthony Martinez
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-06-01
Series:Infectious Diseases and Therapy
Subjects:
Compensated cirrhosis
Glecaprevir
Pibrentasvir
Hepatitis C virus
Infectious diseases
Treatment naïve
Online Access:https://doi.org/10.1007/s40121-023-00823-z

Internet

https://doi.org/10.1007/s40121-023-00823-z

Similar Items